Indications for Promethazine
Promethazine is FDA-approved for allergic conditions (rhinitis, conjunctivitis, urticaria), nausea/vomiting prevention and treatment, sedation (preoperative/postoperative), motion sickness, and as adjunctive therapy for anaphylaxis and postoperative pain control. 1
FDA-Approved Indications
The official FDA labeling specifies the following uses 1:
Allergic Conditions
- Perennial and seasonal allergic rhinitis
- Vasomotor rhinitis
- Allergic conjunctivitis (from inhalant allergens and foods)
- Mild, uncomplicated allergic skin manifestations (urticaria and angioedema)
- Amelioration of allergic reactions to blood or plasma
- Dermographism
Anaphylaxis Management
- Adjunctive therapy to epinephrine and other standard measures after acute manifestations are controlled
Sedation
- Preoperative, postoperative, or obstetric sedation
- Sedation in both children and adults
- Relief of apprehension and production of light sleep from which patients can be easily aroused
Nausea and Vomiting
- Prevention and control of nausea/vomiting associated with certain types of anesthesia and surgery
- Antiemetic therapy in postoperative patients
- Active and prophylactic treatment of motion sickness
Pain Management
- Adjunctive therapy to meperidine or other analgesics for control of postoperative pain
Clinical Context from Guidelines
Procedural Sedation
Promethazine functions as a phenothiazine with antihistamine, sedative, antiemetic, and anticholinergic properties 2, 3. In endoscopic sedation, it has been used as an adjuvant to narcotics and benzodiazepines at doses of 12.5-25 mg IV (infused slowly at 25 mg/min to minimize hypotension), with total doses ranging from 25-50 mg 3.
Antiemetic Use
For breakthrough chemotherapy-induced nausea/vomiting, promethazine is listed as a phenothiazine option at 25 mg suppository PR every 6 hours or 12.5-25 mg PO/IV (central line only) every 4-6 hours 4.
Critical Safety Considerations
Age Restrictions
Promethazine is contraindicated in children less than 2 years of age 1. This is a black-box warning due to risks of respiratory depression and sudden death in young children.
Route-Specific Risks
Injectable promethazine carries serious risks including 3, 5:
- Tissue necrosis and gangrene with inadvertent perivascular extravasation
- Limb-threatening complications with unintentional intra-arterial injection
- Intraneuronal or perineuronal infiltration injuries
The FDA updated labeling in December 2023 to emphasize preference for intramuscular administration over intravenous, and when IV use is necessary, requires dilution and slow administration 5.
Other Contraindications
- Comatose states
- Known hypersensitivity to promethazine or other phenothiazines
- Treatment of lower respiratory tract symptoms including asthma 1
Important Clinical Caveats
Institutional formulary changes: Many hospitals have removed injectable promethazine from formularies following recommendations from the Institute for Safe Medication Practices and American Society of Health-System Pharmacists 6, 7. The availability of safer alternatives (5-HT3 antagonists, dopamine antagonists) with comparable or superior efficacy has driven this shift toward precision antiemetic therapy 6.
Adverse effects include hypotension, respiratory depression, neuroleptic malignant syndrome, and extrapyramidal effects ranging from restlessness to oculogyric crises 2, 3.
Dose reduction requirement: When promethazine is used as an adjuvant, it typically requires reduction in dosage of standard sedation agents due to additive CNS depression 3.